Which patient characteristics or clinical factors guide the decision to use Doxorubicin and Trabectedin as first-line treatment for metastatic or unresectable leiomyosarcoma?

The trial included any patient with Grade 2/3 LMS who presented with metastatic disease or unresectable LMS and was a candidate for this regimen. Having said that, I always make the patient aware of the high risk of having a grade 3 or higher adverse event. The OS benefit demonstrated in the trial i...

The response rates reported are the highest we have seen for this histology. The toxicity profile of AT is clearly better than AI. So by default, the AT regimen is gaining popularity as the regimen of choice. The debate continues about the "maintenance" Trabectedin, and can be individualized based o...